423 related articles for article (PubMed ID: 23792451)
21. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.
Voutsadakis IA
Crit Rev Oncol Hematol; 2023 Jun; 186():103987. PubMed ID: 37059275
[TBL] [Abstract][Full Text] [Related]
22. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
23. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
24. Aspirin use and risk of colorectal cancer according to BRAF mutation status.
Nishihara R; Lochhead P; Kuchiba A; Jung S; Yamauchi M; Liao X; Imamura Y; Qian ZR; Morikawa T; Wang M; Spiegelman D; Cho E; Giovannucci E; Fuchs CS; Chan AT; Ogino S
JAMA; 2013 Jun; 309(24):2563-71. PubMed ID: 23800934
[TBL] [Abstract][Full Text] [Related]
25. Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
Cohen SA; Turner EH; Beightol MB; Jacobson A; Gooley TA; Salipante SJ; Haraldsdottir S; Smith C; Scroggins S; Tait JF; Grady WM; Lin EH; Cohn DE; Goodfellow PJ; Arnold MW; de la Chapelle A; Pearlman R; Hampel H; Pritchard CC
Gastroenterology; 2016 Sep; 151(3):440-447.e1. PubMed ID: 27302833
[TBL] [Abstract][Full Text] [Related]
26. PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
Paleari L; Puntoni M; Clavarezza M; DeCensi M; Cuzick J; DeCensi A
Clin Oncol (R Coll Radiol); 2016 May; 28(5):317-26. PubMed ID: 26712086
[TBL] [Abstract][Full Text] [Related]
27. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
[TBL] [Abstract][Full Text] [Related]
28. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
[TBL] [Abstract][Full Text] [Related]
29. Association of
Ugai T; Zhao M; Shimizu T; Akimoto N; Shi S; Takashima Y; Zhong R; Lau MC; Haruki K; Arima K; Fujiyoshi K; Langworthy B; Masugi Y; da Silva A; Nosho K; Baba Y; Song M; Chan AT; Wang M; Meyerhardt JA; Giannakis M; Väyrynen JP; Nowak JA; Ogino S
Oncoimmunology; 2021; 10(1):1956173. PubMed ID: 34377593
[TBL] [Abstract][Full Text] [Related]
30. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
[TBL] [Abstract][Full Text] [Related]
31. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.
Baba Y; Nosho K; Shima K; Hayashi M; Meyerhardt JA; Chan AT; Giovannucci E; Fuchs CS; Ogino S
Cancer; 2011 Apr; 117(7):1399-408. PubMed ID: 21425139
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.
Wu S; Gan Y; Wang X; Liu J; Li M; Tang Y
J Cancer Res Clin Oncol; 2013 May; 139(5):891-900. PubMed ID: 23435830
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
Nosho K; Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Zepf D; Yan L; Longtine JA; Fuchs CS; Ogino S
Neoplasia; 2008 Jun; 10(6):534-41. PubMed ID: 18516290
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
[TBL] [Abstract][Full Text] [Related]
36. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
Ogino S; Nosho K; Kirkner GJ; Shima K; Irahara N; Kure S; Chan AT; Engelman JA; Kraft P; Cantley LC; Giovannucci EL; Fuchs CS
J Clin Oncol; 2009 Mar; 27(9):1477-84. PubMed ID: 19237633
[TBL] [Abstract][Full Text] [Related]
37. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
[TBL] [Abstract][Full Text] [Related]
38. Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.
Voutsadakis IA
Med Oncol; 2022 May; 39(5):89. PubMed ID: 35568775
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
Rosty C; Young JP; Walsh MD; Clendenning M; Sanderson K; Walters RJ; Parry S; Jenkins MA; Win AK; Southey MC; Hopper JL; Giles GG; Williamson EJ; English DR; Buchanan DD
PLoS One; 2013; 8(6):e65479. PubMed ID: 23785428
[TBL] [Abstract][Full Text] [Related]
40. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]